Live Breaking News & Updates on Source Medical

Stay updated with breaking news from Source medical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Real-World Data Show High Discontinuation Rates for Frontline Atezolizumab/Bevacizumab in HCC

Real-world data from a systemic review of treatment patterns in the United States showed that the majority of patients with hepatocellular carcinoma administered atezolizumab and bevacizumab in the frontline setting discontinued treatment within 12 months, indicating the need for additional research on the effectiveness of this regimen for patients with high-risk disease. ....

United States , Amitg Singal , Department Of Internal Medicine , International Liver Cancer Association Conference , Ut Southwestern Medical Center , Liver Cancer Association , Internal Medicine , Medical Center , Source Medical , Charlson Comorbidity Index , Gastrointestinal Cancer , Hepatocellular Carcinoma ,